Pretzel's mission is to develop groundbreaking therapies leveraging a deep mechanistic understanding of mitochondrial biology. We are developing first-in-class therapeutics that can address mitochondrial dysfunction at its roots - promising medicines that address major unmet needs in a wide range of diseases, some of which lack meaningful treatment options today.As Chief Operating Officer, my scope of responsibility includes general operational management, fund raising & investor relations, business development, board management, corporate finance, and intellectual property, among other functions. I joined the company at the seed stage and was part of the core team that raised the series A.

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by illuminating the dark genome and decoding the repeatome within – the vast stretches of uncharted genetic material comprising repeat sequence motifs derived from the integration of viruses into the human genome throughout evolution.

Provide business development and operational support, strategy and execution for early to mid stage biotechnology companies.• Business strategy & operational execution• Negotiation & closing of licenses• Venture fundraising• Financial planning; budget creation & management• Program management• Technical & commercial diligence• Experience in diverse therapeutic areas & modalities

• Brought on by investors and founders to lead company in turnaround situation; led company in partnership with CSO and Executive Chair, reporting to the Board• Closed $8.6M seed financing and $1.5M SBIR grant• Completed in-licensing of complementary preclinical program to Metera on favorable terms; progressed lead asset from pre-candidate selection to IND-enabling studies• Created company strategy, full program plan for 2 preclinical programs, budget & detailed business plan; led all aspects of financial and day-to-day business operational management• Built team of expert consultants, expanded Board, hired world-class CSO

Decibel signed a broad R&D collaboration with Regeneron in November 2017 which was later expanded and ultimately led to the company's acquisition in August 2023.

• Led investor relations efforts for FORUM and related corporate development activities• Led early-stage (Phase 1 & 2) program teams as well as safety task force for Phase 3 asset

F-Prime Capital Partners (fka Fidelity Biosciences) invests venture capital in private biopharmaceutical, medical technology, and healthcare IT and services companies.http://fprimecapital.com/

Entrega, Inc. is a portfolio company of Enlight Biosciences / PureTech Health, developing a groundbreaking technology for oral delivery of peptides, proteins, and poorly bioavailable small molecules.

Chief Business Officer at Enlight Biosciences, a unique venture creation firm established by PureTech Ventures (now PureTech Health) in partnership with leading global pharmaceutical companies. Founded 3 life sciences companies (interim executive management, business development and day-to-day operations); managed relationships with Enlight’s 7 pharmaceutical partners and business operations for Enlight Biosciences itself.

Led business planning and strategy; managed day-to-day operations, long-term operational planning; buy-side business development; competitive intelligence

Buy-side M&A for Novartis Pharma Division; operational finance (organizational restructuring and ensuring bottom-line impact)

Experience throughout the healthcare industry including pharmaceutical, biotech, payor / provider and private equity clients in US, EU and Japan; functional specialties including operations, strategy and commercial due diligence.